We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cutaneous Lupus Registry

This study is currently recruiting participants.
Verified May 2016 by Ben Chong, University of Texas Southwestern Medical Center
Sponsor:
ClinicalTrials.gov Identifier:
NCT01266915
First Posted: December 24, 2010
Last Update Posted: May 12, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Ben Chong, University of Texas Southwestern Medical Center
  Purpose

Approximately 1.4 million individuals in the United States have systemic lupus erythematosus, and about 85% of these individuals develop skin lesions at some point of their disease. Cutaneous lupus erythematosus represents the skin manifestations of systemic lupus erythematosus, and can appear in people with or without systemic lupus. It is a mentally, physically, and emotionally debilitating disease that affects both the quality of life and social well-being of those affected.

The cause of cutaneous lupus is not completely understood, but likely includes multiple factors from our genes and the environment. Multiple genetic studies with small numbers of cutaneous lupus patients have been performed to determine which genes are associated with cutaneous lupus. This study aims to accumulate even larger numbers of patients to confidently identify genes and the proteins they encode that could contribute greatly to the formation of cutaneous lupus. The discovery of these genes and proteins would help not only uncover how cutaneous lupus forms, but also improve our abilities to diagnose this disease and predict its course, and stimulate new drug development.


Condition
Lupus Erythematosus

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Molecular Studies on Cutaneous Lupus

Further study details as provided by Ben Chong, University of Texas Southwestern Medical Center:

Primary Outcome Measures:
  • Genes [ Time Frame: 5 years ]
  • Proteins (ie. signaling proteins, autoantibodies) [ Time Frame: 5 years ]

Estimated Enrollment: 500
Study Start Date: January 2009
Estimated Study Completion Date: December 2020
Estimated Primary Completion Date: December 2020 (Final data collection date for primary outcome measure)
Groups/Cohorts
Control group
Normal disease free (non lupus) subjects
Diseased Control
Diseased group 1
Those subjects with systemic lupus erythematosus.
Diseased group 2
Subjects diagnosed with cutaneous lupus.

Detailed Description:

The purpose of this study is to create a national registry of patients with cutaneous lupus patients in order to address many unknown questions about this disease. Specifically, we are interested in better understanding the causes of cutaneous lupus and improving our methods of diagnosis, prognosis, and management of this disease. We plan to use information from all patient sources, including medical histories, clinical information, laboratory data, and blood and skin samples in order to answer these questions.

Each study patient will be asked to complete a series of questionnaires, which, for example, will ask about cutaneous and/or systemic lupus history, past medical history, family history, quality of life, and sun protective habits. Patients will be also asked to donate blood and skin samples and undergo digital photography of affected areas. No treatments will be administered as part of this study, but all participants will be notified of clinical trials being conducted at UT Southwestern. This study is for the purpose of data collection only. Patients will be asked to be followed on an annual basis for five years.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Subjects diagnosed with Lupus Erythematosus
Criteria

Inclusion Criteria:

  • Diagnosed with cutaneous lupus erythematosus and/or systemic lupus erythematosus by clinical, laboratory, and histopathological findings
  • Ability to speak and read English or Spanish at a 6th grade reading level (a translator will be available with additional consent forms in Spanish)
  • Ability to give written informed consent

Exclusion Criteria:

  • Less than 18 years of age, since the characteristics of the disease in these subjects could be very different
  • Due to a medication, in which its discontinuation results in the resolution of cutaneous lupus, since the characteristics of the disease in these subjects could be very different
  • Medical conditions who do not warrant a skin biopsy
  • Unable to give written, informed consent or undergo a skin biopsy and/or venipuncture for any other reason
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01266915


Contacts
Contact: Benjamin Chong, MD, MSCS 214-648-3427 skinlupus.registry@utsouthwestern.edu

Locations
United States, Texas
University of Texas Southwestern Medical Center Dallas Recruiting
Dallas, Texas, United States, 75390
Contact: Benjamin F Chong, MD, MSCS    214-648-3427    skinlupus.registry@utsouthwestern.edu   
Sponsors and Collaborators
University of Texas Southwestern Medical Center
  More Information

Responsible Party: Ben Chong, Assistant Professor, University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier: NCT01266915     History of Changes
Other Study ID Numbers: 112008-008
First Submitted: December 23, 2010
First Posted: December 24, 2010
Last Update Posted: May 12, 2016
Last Verified: May 2016

Keywords provided by Ben Chong, University of Texas Southwestern Medical Center:
SCLE
CLE
DLE